Previous Close | 11.03 |
Open | 10.83 |
Bid | 10.95 x 28000 |
Ask | 10.96 x 3100 |
Day's Range | 10.82 - 11.15 |
52 Week Range | 6.78 - 11.15 |
Volume | |
Avg. Volume | 13,277,177 |
Market Cap | 12.216B |
Beta (5Y Monthly) | 1.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.56 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Nov 27, 2017 |
1y Target Est | 10.73 |
Subscribe to Yahoo Finance Plus to view Fair Value for TEVA
The stock of Teva Pharmaceutical Industries (NYSE: TEVA) closed out the trading week in style, popping by almost 6% on Friday. The generic-drug specialist was the subject of a recommendation upgrade from a noted financial institution, hence the share price rise. Analyst Jason Gerberry from the bank's securities unit raised his recommendation on Teva from neutral to buy.
Berkshire Hathaway cut bait with the struggling drugmaker Teva Pharmaceutical Industries in late 2021.
Management confirmed financial forecasts it had issued earlier. The drug company's second-quarter results were roughly in line with expectations.